Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688687.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688687.SS and 80,000+ other tickers.
See exactly how 688687.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688687.SS and 80,000+ other tickers.
Established in 2008 and based in Beijing, China, Beijing Kawin Technology Share-Holding Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary emphasis on treatments for liver conditions within the Chinese market. Its key offerings include recombinant human interferon alfa-2b injection and compound glycyrrhizin. Beyond its own product line, the company supplies active pharmaceutical ingredients (APIs) and delivers comprehensive clinical research services for advancing biological products. These services encompass the fermentation and…
No recent news available.